AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
orphenadrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| opioid receptor antagonists/agonists, morphinan derivates | 1999 | 83-98-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.12 | g | O |
| 0.12 | g | P |
| 0.20 | g | O |
| 0.20 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 21.21 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.014 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.594 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 30.690 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 58.345 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 26.590 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 31.720 | % | High | 1 |
| herg | hERG pIC50 | 5.247 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 5.420 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 14.997 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 20.830 | % | High | 1 |
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.492 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.472 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 127.350 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 33.750 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.589 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.73 | |
| pppb | Pig plasma protein binding (% unbound) | 59.110 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 1.091 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 288.403 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 60.600 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 39.620 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 963.829 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 10, 1957 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia viral | 477.03 | 26.97 | 111 | 5678 | 8712 | 90613946 |
| Soft tissue disorder | 369.27 | 26.97 | 79 | 5710 | 4211 | 90618447 |
| Herpes zoster | 294.93 | 26.97 | 136 | 5653 | 94508 | 90528150 |
| Oral pain | 232.75 | 26.97 | 85 | 5704 | 32598 | 90590060 |
| Liver function test abnormal | 212.87 | 26.97 | 90 | 5699 | 50755 | 90571903 |
| Leukopenia | 176.07 | 26.97 | 98 | 5691 | 100612 | 90522046 |
| Sternal fracture | 154.16 | 26.97 | 36 | 5753 | 2851 | 90619807 |
| Libido increased | 132.48 | 26.97 | 29 | 5760 | 1715 | 90620943 |
| Arthritis | 128.28 | 26.97 | 97 | 5692 | 167218 | 90455440 |
| Soft tissue injury | 127.23 | 26.97 | 29 | 5760 | 2063 | 90620595 |
| Hostility | 124.83 | 26.97 | 29 | 5760 | 2244 | 90620414 |
| Peripheral swelling | 124.53 | 26.97 | 142 | 5647 | 412964 | 90209694 |
| Post-traumatic neck syndrome | 121.92 | 26.97 | 29 | 5760 | 2485 | 90620173 |
| Blood cholesterol increased | 113.75 | 26.97 | 99 | 5690 | 207913 | 90414745 |
| Fibromyalgia | 112.45 | 26.97 | 98 | 5691 | 206171 | 90416487 |
| Nightmare | 89.28 | 26.97 | 38 | 5751 | 21687 | 90600971 |
| Concussion | 79.43 | 26.97 | 29 | 5760 | 11062 | 90611596 |
| Personality disorder | 76.17 | 26.97 | 29 | 5760 | 12415 | 90610243 |
| Tenderness | 75.38 | 26.97 | 36 | 5753 | 26832 | 90595826 |
| Middle insomnia | 74.50 | 26.97 | 31 | 5758 | 16720 | 90605938 |
| Synovitis | 71.17 | 26.97 | 96 | 5693 | 329656 | 90293002 |
| Anaemia | 70.57 | 26.97 | 99 | 5690 | 352703 | 90269955 |
| Muscle twitching | 69.64 | 26.97 | 33 | 5756 | 24169 | 90598489 |
| Infection | 59.96 | 26.97 | 93 | 5696 | 362001 | 90260657 |
| Rib fracture | 58.08 | 26.97 | 30 | 5759 | 26405 | 90596253 |
| Poor quality sleep | 57.08 | 26.97 | 29 | 5760 | 24664 | 90597994 |
| Body temperature increased | 53.16 | 26.97 | 34 | 5755 | 44676 | 90577982 |
| Irritability | 49.68 | 26.97 | 30 | 5759 | 35632 | 90587026 |
| Therapeutic product effect incomplete | 42.57 | 26.97 | 57 | 5732 | 193839 | 90428819 |
| Soft tissue swelling | 42.21 | 26.97 | 11 | 5778 | 1367 | 90621291 |
| Sedation | 41.46 | 26.97 | 30 | 5759 | 48141 | 90574517 |
| Dysgeusia | 41.33 | 26.97 | 31 | 5758 | 52529 | 90570129 |
| Joint swelling | 39.34 | 26.97 | 94 | 5695 | 503206 | 90119452 |
| Incorrect route of product administration | 37.91 | 26.97 | 29 | 5760 | 50597 | 90572061 |
| Oculogyric crisis | 35.82 | 26.97 | 11 | 5778 | 2468 | 90620190 |
| Feeling hot | 34.44 | 26.97 | 33 | 5756 | 77975 | 90544683 |
| Tremor | 32.04 | 26.97 | 44 | 5745 | 153129 | 90469529 |
| Vertigo | 31.70 | 26.97 | 30 | 5759 | 69781 | 90552877 |
| Anxiety | 31.08 | 26.97 | 64 | 5725 | 309708 | 90312950 |
| Flushing | 29.19 | 26.97 | 32 | 5757 | 88459 | 90534199 |
| Drug ineffective | 28.16 | 26.97 | 167 | 5622 | 1384131 | 89238527 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Convulsive threshold lowered | 32.74 | 28.89 | 6 | 778 | 509 | 42620042 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia viral | 303.63 | 25.64 | 76 | 5097 | 11081 | 110573045 |
| Soft tissue disorder | 213.41 | 25.64 | 46 | 5127 | 3478 | 110580648 |
| Sternal fracture | 160.38 | 25.64 | 36 | 5137 | 3280 | 110580846 |
| Herpes zoster | 140.80 | 25.64 | 78 | 5095 | 108301 | 110475825 |
| Soft tissue injury | 133.80 | 25.64 | 29 | 5144 | 2247 | 110581879 |
| Libido increased | 130.64 | 25.64 | 29 | 5144 | 2510 | 110581616 |
| Post-traumatic neck syndrome | 130.01 | 25.64 | 29 | 5144 | 2566 | 110581560 |
| Hostility | 128.91 | 25.64 | 29 | 5144 | 2667 | 110581459 |
| Oral pain | 119.56 | 25.64 | 50 | 5123 | 37394 | 110546732 |
| Liver function test abnormal | 101.65 | 25.64 | 54 | 5119 | 68896 | 110515230 |
| Concussion | 87.16 | 25.64 | 29 | 5144 | 11509 | 110572617 |
| Leukopenia | 85.27 | 25.64 | 64 | 5109 | 148727 | 110435399 |
| Personality disorder | 84.12 | 25.64 | 29 | 5144 | 12808 | 110571318 |
| Nightmare | 76.43 | 25.64 | 37 | 5136 | 38826 | 110545300 |
| Arthritis | 76.43 | 25.64 | 63 | 5110 | 167523 | 110416603 |
| Fibromyalgia | 75.34 | 25.64 | 63 | 5110 | 170846 | 110413280 |
| Middle insomnia | 70.90 | 25.64 | 29 | 5144 | 20473 | 110563653 |
| Tenderness | 67.00 | 25.64 | 31 | 5142 | 29406 | 110554720 |
| Blood cholesterol increased | 65.15 | 25.64 | 60 | 5113 | 184725 | 110399401 |
| Peripheral swelling | 63.65 | 25.64 | 86 | 5087 | 403948 | 110180178 |
| Poor quality sleep | 62.13 | 25.64 | 29 | 5144 | 28048 | 110556078 |
| Muscle twitching | 60.36 | 25.64 | 29 | 5144 | 29906 | 110554220 |
| Rib fracture | 59.98 | 25.64 | 30 | 5143 | 33740 | 110550386 |
| Sedation | 58.71 | 25.64 | 38 | 5135 | 69645 | 110514481 |
| Body temperature increased | 54.02 | 25.64 | 33 | 5140 | 54680 | 110529446 |
| Irritability | 47.62 | 25.64 | 29 | 5144 | 47780 | 110536346 |
| Therapeutic product effect incomplete | 45.24 | 25.64 | 54 | 5119 | 223751 | 110360375 |
| Synovitis | 44.09 | 25.64 | 59 | 5114 | 274033 | 110310093 |
| Dysgeusia | 42.04 | 25.64 | 31 | 5142 | 69954 | 110514172 |
| Anxiety | 41.92 | 25.64 | 65 | 5108 | 345013 | 110239113 |
| Incorrect route of product administration | 39.89 | 25.64 | 29 | 5144 | 64032 | 110520094 |
| Migraine | 39.00 | 25.64 | 44 | 5129 | 171608 | 110412518 |
| Feeling hot | 38.89 | 25.64 | 33 | 5140 | 91073 | 110493053 |
| Oculogyric crisis | 34.48 | 25.64 | 11 | 5162 | 3821 | 110580305 |
| Vertigo | 34.10 | 25.64 | 30 | 5143 | 86840 | 110497286 |
| Soft tissue swelling | 33.39 | 25.64 | 9 | 5164 | 1740 | 110582386 |
| Tremor | 33.21 | 25.64 | 44 | 5129 | 202188 | 110381938 |
| Flushing | 33.02 | 25.64 | 32 | 5141 | 104704 | 110479422 |
| Arthralgia | 32.76 | 25.64 | 95 | 5078 | 779537 | 109804589 |
| Infection | 31.73 | 25.64 | 59 | 5114 | 362141 | 110221985 |
| Periarthritis | 26.17 | 25.64 | 9 | 5164 | 3941 | 110580185 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03BC01 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Ethers, chemically close to antihistamines |
| ATC | M03BC51 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Ethers, chemically close to antihistamines |
| ATC | N04AB02 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers chemically close to antihistamines |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D009125 | Muscle Relaxants, Central |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D010276 | Parasympatholytics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018680 | Cholinergic Antagonists |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| MeSH PA | D018727 | Muscarinic Antagonists |
| MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
| MeSH PA | D065686 | Cytochrome P-450 CYP2B6 Inhibitors |
| FDA PE | N0000175730 | Centrally-mediated Muscle Relaxation |
| FDA EPC | N0000175737 | Muscle Relaxant |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:37955 | H<small><sub>1</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:48876 | muscarinic antagonist |
| CHEBI has role | CHEBI:50370 | parasympatholytic |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
| CHEBI has role | CHEBI:60643 | NMDA receptor antagonist |
| CHEBI has role | CHEBI:66956 | antidyskinesia agent |
Related Drugs by ATC class:
N04AB Ethers chemically close to antihistamines 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Parkinsonism | indication | 32798002 | |
| Spasticity | indication | 221360009 | |
| Necrotizing enterocolitis in fetus OR newborn | contraindication | 2707005 | |
| Tachyarrhythmia | contraindication | 6285003 | |
| Alcoholism | contraindication | 7200002 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Poisoning by acetaminophen | contraindication | 70273001 | |
| Agoraphobia | contraindication | 70691001 | DOID:593 |
| Factor II deficiency | contraindication | 73975000 | |
| Reye's syndrome | contraindication | 74351001 | DOID:14525 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Hemophilia | contraindication | 90935002 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Obstruction of duodenum | contraindication | 95532008 | DOID:3558 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
| Seizure disorder | contraindication | 128613002 | |
| Obsessive-compulsive disorder | contraindication | 191736004 | DOID:10933 |
| Insomnia | contraindication | 193462001 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Panic disorder | contraindication | 371631005 | DOID:594 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Myocardial infarction in recovery phase | contraindication | 418044006 | |
| Acute erosive gastritis | contraindication | 444926003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.52 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 9 subunit alpha | Ion channel | BLOCKER | IC50 | 4.76 | WOMBAT-PK | CHEMBL | |||
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 7.96 | WOMBAT-PK | CHEMBL | |||
| Sodium channel protein type 10 subunit alpha | Ion channel | BLOCKER | IC50 | 5.20 | WOMBAT-PK | CHEMBL | |||
| Sodium channel protein type 1 subunit alpha | Ion channel | BLOCKER | IC50 | 4.89 | WOMBAT-PK | CHEMBL | |||
| Sodium channel protein type 4 subunit alpha | Ion channel | BLOCKER | Ki | 5.66 | WOMBAT-PK | CHEMBL | |||
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | IC50 | 4.89 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.67 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.55 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.28 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.06 | DRUG MATRIX | |||||
| Histamine H2 receptor | GPCR | Ki | 5.17 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.39 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.87 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.43 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.77 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.70 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6.40 | DRUG MATRIX | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 4.90 | CHEMBL | |||||
| Glutamate [NMDA] receptor | Ion channel | Ki | 5.22 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.09 | DRUG MATRIX | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.17 | WOMBAT-PK | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.61 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Ki | 5.58 | DRUG MATRIX | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.90 | DRUG MATRIX | |||||
| Histamine H1 receptor | GPCR | IC50 | 6.79 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019866 | VUID |
| N0000147952 | NUI |
| D00774 | KEGG_DRUG |
| 4682-36-4 | SECONDARY_CAS_RN |
| 4018819 | VANDF |
| 4018820 | VANDF |
| 4019866 | VANDF |
| C0029309 | UMLSCUI |
| CHEBI:7789 | CHEBI |
| CHEMBL900 | ChEMBL_ID |
| CHEMBL1201023 | ChEMBL_ID |
| DB01173 | DRUGBANK_ID |
| CHEMBL1200395 | ChEMBL_ID |
| D009966 | MESH_DESCRIPTOR_UI |
| 4601 | PUBCHEM_CID |
| 7251 | IUPHAR_LIGAND_ID |
| 658 | INN_ID |
| 341-69-5 | SECONDARY_CAS_RN |
| AL805O9OG9 | UNII |
| 155039 | RXNORM |
| 4456 | MMSL |
| 5206 | MMSL |
| d00966 | MMSL |
| 001648 | NDDF |
| 001649 | NDDF |
| 001650 | NDDF |
| 35035001 | SNOMEDCT_US |
| 372714007 | SNOMEDCT_US |
| 387167001 | SNOMEDCT_US |
| 395813009 | SNOMEDCT_US |
| AL805O9OG9 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-2011 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 10 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0022 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 13 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3222 | INJECTION | 30 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Orphenadrine citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6182 | INJECTION | 60 mg | INTRAMUSCULAR | ANDA | 15 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-283 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 12 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-177 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 9 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-099 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 16 sections |
| Orphenadrine Citrate, Aspirin and Caffeine | HUMAN PRESCRIPTION DRUG LABEL | 3 | 21695-726 | TABLET, MULTILAYER | 50 mg | ORAL | ANDA | 12 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-651 | INJECTION, SOLUTION | 30 mg | INTRAVENOUS | ANDA | 16 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-088 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 16 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33358-274 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 12 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-559 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 11 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-407 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-407 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-480 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-363 | TABLET | 100 mg | ORAL | ANDA | 13 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49999-046 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 16 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0169 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2438 | INJECTION | 30 mg | INTRAMUSCULAR | ANDA | 14 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3150 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| Orphenadrine Citrate Aspirin Caffeine | HUMAN PRESCRIPTION DRUG LABEL | 3 | 50564-554 | TABLET | 25 mg | ORAL | ANDA | 10 sections |
| Orphenadrine Citrate Aspirin Caffeine | HUMAN PRESCRIPTION DRUG LABEL | 3 | 50564-555 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
| Norgesic Forte | HUMAN PRESCRIPTION DRUG LABEL | 3 | 50991-999 | TABLET, MULTILAYER | 50 mg | ORAL | ANDA | 12 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-527 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 13 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-5430 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 14 sections |
| ORPHENADRINE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4102 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 16 sections |
| Orphenadrine Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60760-810 | TABLET, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 12 sections |
| ORPHENGESIC FORTE | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61825-302 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| ORPHENGESIC FORTE | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61825-302 | TABLET | 50 mg | ORAL | ANDA | 11 sections |
| Norgesic | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61825-305 | TABLET | 25 mg | ORAL | ANDA | 11 sections |